Search Result
Results for "
α-glucosidases
" in MedChemExpress (MCE) Product Catalog:
3
Biochemical Assay Reagents
Cat. No. |
Product Name |
Target |
Research Areas |
Chemical Structure |
-
- HY-117721
-
-
-
- HY-149342
-
|
Glucosidase
|
Metabolic Disease
|
α-Glucosidase-IN-29 (compound 19) is a α-glucosidases inhibitor (IC50=1.21 μM, Ki=1.80 μM). α-Glucosidase-IN-29 ca be used for research of diabetes and related diseases .
|
-
-
- HY-117603
-
|
Glucokinase
|
Infection
|
CM-10-18 is a potent and orally active inhibitor of both α-glucosidases I and II in vitro and in treated animals. CM-10-18 inhibits DENV infection of cultured human cells and reduces the peak viremia of DENV in mice .
|
-
-
- HY-145273
-
|
Glucosidase
|
Infection
|
EB-0150 is a potent inhibitor of ER α-glucosidases (α-Glu) Iand II with IC50s of 0.73 and 0.0337 μM, respectively. EB-0150 is a N-substituted derivative of valiolamine with broad-spectrum antiviral. EB-0150 has the potential for the reseach of broad-spectrum agent against the existing and emerging viruses .
|
-
-
- HY-145275
-
|
Glucosidase
|
Infection
|
EB-0176 is a potent inhibitor of ER α-glucosidases (α-Glu) Iand II with IC50s of 0.6439 and 0.0011 μM, respectively. EB-0176 is a N-substituted derivative of valiolamine with broad-spectrum antiviral. EB-0176 has the potential for the reseach of broad-spectrum agent against the existing and emerging viruses .
|
-
-
- HY-145274
-
|
Glucosidase
|
Infection
|
EB-0156 is a potent inhibitor of ER α-glucosidases (α-Glu) Iand II with IC50s of 0.0479 and less than 0.001 μM, respectively. EB-0156 is a N-substituted derivative of valiolamine with broad-spectrum antiviral. EB-0156 has the potential for the reseach of broad-spectrum agent against the existing and emerging viruses .
|
-
-
- HY-150560
-
|
Glucosidase
|
Metabolic Disease
|
α-Glucosidase-IN-11 is a highly permeable competitive α-glucosidase inhibitor with the IC50 value of 0.56 μM. α-Glucosidase-IN-11 binds to Trp residues in α-glucosidase and regulates protein folding. α-Glucosidase-IN-11 can be used to regulate blood glucose levels .
|
-
-
- HY-156078
-
|
Glucosidase
|
Metabolic Disease
|
α-Glucosidase-IN-32 (compound f26) is a reversible, noncompetitive and orally active α-glucosidase inhibitor with an IC50 value of 3.07 μM. α-Glucosidase-IN-32 complex with α-glucosidase through hydrogen bonds and hydrophobic interactions, led to changes in the conformation and secondary strictures of α-glucosidase and further the inhibition of the enzymatic activity. α-Glucosidase-IN-32 can be used for diabetic disease research .
|
-
-
- HY-157489
-
|
Glucosidase
|
Metabolic Disease
|
α-Glucosidase-IN-47 (compound 8H) is a non-competitive α-glucosidase (α-glucosidase) inhibitor with IC50 value is 38.2 μM and Ki value is 38.2 μM. α-Glucosidase-IN-47 can be used in diabetes research. .
|
-
-
- HY-124662
-
|
Flavivirus
Dengue virus
Glucosidase
|
Infection
|
IHVR-19029 is a potent endoplasmic reticulum (ER) α-glucosidases I and II inhibitor, with an IC50 of 0.48 μM for ER a-glucosidase I. IHVR-19029 efficiently blocks the replication of several hemorrhagic fever viruses, such as Dengue virus (DENV), Ebola virus (EBOV) and Rift Valley fever virus. The combination of IHVR-19029 with Favipiravir (HY-14768) improves the antiviral efficacy .
|
-
-
- HY-148575
-
|
Glucosidase
|
Metabolic Disease
|
α-Glucosidase-IN-23 is an orally active α-Glucosidase inhibitor. α-Glucosidase-IN-23 decreases blood glucose by a-glucosidase inhibition with an IC50 value of 4.48 μM. α-Glucosidase-IN-23 can be used for the research of diabetes .
|
-
-
- HY-162286
-
-
-
- HY-162287
-
-
-
- HY-149341
-
|
Glucosidase
|
Metabolic Disease
|
α-Glucosidase-IN-28 (Compound 18) is a α-Glucosidase inhibitor (IC50: 0.62 μM, Ki: 3.93 μM). α-Glucosidase-IN-28 binds to α-glucosidase at the original binding site (OBS), and forms multiple hydrophobic interactions with nearby amino acids. α-Glucosidase-IN-28 can be used for research of diabetes and related diseases .
|
-
-
- HY-115978
-
|
Glucosidase
|
Metabolic Disease
|
α-Glucosidase-IN-2 (compound 5d) is a potent α-Glucosidase inhibitor with an IC50 of 9.48 µM. α-Glucosidase-IN-2 is an antidiabetic agent .
|
-
-
- HY-N11512
-
|
Glucosidase
|
Metabolic Disease
|
α-Glucosidase-IN-24 (Compound 13) is an α-Glucosidase inhibitor with an IC50 of 451 μM. α-Glucosidase-IN-24 can be isolated from Swertia kouitchensis .
|
-
-
- HY-155372
-
|
Glucosidase
|
Metabolic Disease
|
α-Glucosidase-IN-39 is a potent inhibitor of α-glucosidase enzyme with an IC50 of 869.06 ppm. α-Glucosidase-IN-39 can used in study antidiabetic .
|
-
-
- HY-163066
-
|
Glucosidase
|
Metabolic Disease
|
α-Glucosidase-IN-44 (compound IT4) is an inhibitor of α-glucosidase with IC50 value of 2.35 μM. α-Glucosidase-IN-44 has an oral activity. α-Glucosidase-IN-44 suppresses fasting blood glucose levels in diabetic mice .
|
-
-
- HY-149579
-
|
Glucosidase
|
Metabolic Disease
|
α-Glucosidase-IN-36 (compound 5g) is a potent α-glucosidase inhibitor, with an IC50 of 6.69 ± 0.18 μM, Ki and Kis of 1.65 μM and 4.54 μM, respectively. α-Glucosidase-IN-36 may inhibit α-glucosidase activity by binding with its active site as well as changing the secondary structure of α-glucosidase. α-Glucosidase-IN-36 can be used for type 2 diabetes mellitus (T2DM) research .
|
-
-
- HY-W783267
-
|
Glucosidase
|
Metabolic Disease
|
α-Glucosidase-IN-35 (compound 1) is a kind of chromene. α-Glucosidase-IN-35 can be isolated from the aqueous extract of the aerial parts of Brickellia cavanillesii. α-Glucosidase-IN-35 is a potent inhibitor of α-glucosidase with an IC50 value of 0.169 mg/mL .
|
-
-
- HY-147823
-
|
Glucosidase
|
Metabolic Disease
|
α-Glucosidase-IN-6 (compound 18) is a competitive α-glucosidase inhibitor with an IC50 of 5.69 µM. α-Glucosidase-IN-6 has anti-diabetic potential .
|
-
-
- HY-157488
-
|
Glucosidase
|
Metabolic Disease
|
α-Glucosidase-IN-46 is a potent α-glucosidase inhibitor with an IC50 of 26.0 μM. α-Glucosidase-IN-46 can be used for the research of type 2 diabetes .
|
-
-
- HY-161318
-
|
Glucosidase
|
Metabolic Disease
|
α-Glucosidase-IN-52 (Compound 3h) is an α-glucosidase inhibitor with an IC50 of 2.8 μM. α-Glucosidase-IN-52 can be used for diabetes research .
|
-
-
- HY-149668
-
|
Glucosidase
|
Metabolic Disease
|
α-Glucosidase-IN-41 (compound 5o) is a potent α-glucosidase inhibitor. α-Glucosidase-IN-41 can arise the changed secondary structure of α-Glu to hinder enzyme catalytic activity. α-Glucosidase-IN-41 can be used for diabetes mellitus research .
|
-
-
- HY-149676
-
|
Glucosidase
|
Metabolic Disease
|
α-Glucosidase-IN-42 (Compound 26) is a 9-O-berberrubine carboxylate derivative. α-Glucosidase-IN-42 has potent α-glucosidase inhibitory activities with an IC50 value in the range of 1.61 μM. α-Glucosidase-IN-42 can be used for the research of antidiabetic .
|
-
-
- HY-147718
-
|
Glutaminase
|
Metabolic Disease
|
α-Glucosidase-IN-5 (compound 8) is a potent α-glucosidase inhibitor with an IC50 of 57.9 µM. α-Glucosidase-IN-5 has the potential for the research of diabetes mellitus .
|
-
-
- HY-151142
-
|
Glucosidase
|
Metabolic Disease
|
α-Glucosidase-IN-18 (7B) is an orally active α-glucosidase inhibitor with an IC50 value of 3.96 μM. α-Glucosidase-IN-18 has antidiabetic activity .
|
-
-
- HY-147964
-
|
Glucosidase
|
Metabolic Disease
|
α-Glucosidase-IN-9 (compound 7) is a potent α-glucosidase inhibitor, with an IC50 of 55.6 μM. α-Glucosidase-IN-9 can be used for type II diabetes research .
|
-
-
- HY-147965
-
|
Glucosidase
|
Metabolic Disease
|
α-Glucosidase-IN-10 (compound 13) is a potent α-glucosidase inhibitor, with an IC50 of 92.7 μM. α-Glucosidase-IN-10 can be used for type II diabetes research .
|
-
-
- HY-151141
-
|
Glucosidase
|
Metabolic Disease
|
α-Glucosidase-IN-17 (Compound 12B) is a potent, orally active α-glucosidase inhibitor with an IC50 of 3.79 μM. α-Glucosidase-IN-17 shows antidiabetic activity .
|
-
-
- HY-151135
-
|
Glucosidase
|
Metabolic Disease
|
α-Glucosidase-IN-15 (Compound 14B) is a potent, orally active α-glucosidase inhibitor with an IC50 of 3.34 μM. α-Glucosidase-IN-15 shows antidiabetic activity .
|
-
-
- HY-151145
-
|
Glucosidase
|
Metabolic Disease
|
α-Glucosidase-IN-21 (Compound 2B) is a potent, orally active α-glucosidase inhibitor with an IC50 of 2.62 μM. α-Glucosidase-IN-21 shows anti-diabetic activity .
|
-
-
- HY-151143
-
|
Glucosidase
|
Metabolic Disease
|
α-Glucosidase-IN-19 (Compound 6B) is a potent, orally active α-glucosidase inhibitor with an IC50 of 3.63 μM. α-Glucosidase-IN-19 shows anti-diabetic activity .
|
-
-
- HY-151144
-
|
Glucosidase
|
Metabolic Disease
|
α-Glucosidase-IN-20 (Compound 3B) is a potent, orally active α-glucosidase inhibitor with an IC50 of 3.01 μM. α-Glucosidase-IN-20 shows anti-diabetic activity .
|
-
-
- HY-157311
-
|
Glucosidase
|
Cancer
|
α-Glucosidase-IN-45 (compound 11E) is an inhibitor of α-glucosidase. α-Glucosidase-IN-45 is a novel indol-fused pyrano[2,3-D]pyrimidine compound .
|
-
-
- HY-N12664
-
|
Glucosidase
|
Metabolic Disease
|
α-Glucosidase-IN-54 (compound 2) is a α-glucosidase inhibitor with the IC50 of 0.011 mM, and can be isolated form Syzygium jambos (L.). α-Glucosidase-IN-54 can be used for study of diabetes .
|
-
-
- HY-146225
-
|
Glucosidase
|
Metabolic Disease
|
α-Amylase/α-Glucosidase-IN-2 (compound 5) is a potent α-amylase and α-glucosidase dual inhibitor with IC50 values of 13.02, 13.09 µM for α-amylase and α-glucosidase, respectively. α-Amylase/α-Glucosidase-IN-2 has the potential for the research of diabetic complications .
|
-
-
- HY-146156
-
-
-
- HY-150960
-
-
-
- HY-155344
-
|
Glucosidase
|
Metabolic Disease
|
α-Glucosidase-IN-38 (Compound 11j) is a potent inhibitor of α-glucosidase inhibitor with IC50 of 12.44±0.38 μM.α-Glucosidase-IN-38 plays an important role in Diabetes mellitus (DM) .
|
-
-
- HY-147711
-
|
Glucosidase
|
Metabolic Disease
|
α-Amylase/α-Glucosidase-IN-1 (compound 33) is a potent α-amylase/α-glucosidase inhibitor with IC50s of 2.01, 2.09 µM for α-amylase and α-glucosidase, respectively. Kinetic studies predict that α-Amylase/α-Glucosidase-IN-1 has the potential of anti hyperglycemia .
|
-
-
- HY-154998
-
|
Glucosidase
|
Metabolic Disease
|
α-Glucosidase-IN-27 (compound 8l) is an α-glucosidase inhibitor (IC50=25.78 μM). α-Glucosidase-IN-27 has the potential to study type 2 diabetes (D2M) .
|
-
-
- HY-N12347
-
|
Others
|
Inflammation/Immunology
|
α-Glucosidase-IN-37 (Compound 11) moderately inhibits LPS-induced NO production with an IC50 value of 23.7 μM in macrophages. α-Glucosidase-IN-37 has weak inhibitory activity against α-Glucosidase .
|
-
-
- HY-150959
-
-
-
- HY-150961
-
-
-
- HY-162262
-
-
-
- HY-162395
-
-
-
- HY-N12721
-
-
-
- HY-147879
-
-
-
- HY-156447
-
|
Glucosidase
|
Metabolic Disease
|
α-Glucosidase-IN-40 (compound 5) is a noncompetitive α-glucosidase enzyme inhibitor with an IC50 of 24.62 μM .
|
-
- HY-151138
-
|
Glucosidase
|
Metabolic Disease
|
α-Glucosidase-IN-16 is a potent and orally active α-glucosidase inhibitor with an IC50 value of 3.28 μM. α-Glucosidase-IN-16 can reduce the level of blood glucose in Streptozotocin-induced diabetic rats. Antidiabetic activity .
|
-
- HY-149332
-
|
Glucosidase
|
Metabolic Disease
|
α-Glucosidase-IN-26 (Compound 7i) is an α-glucosidase inhibitor (IC50=4.63 µM). α-Glucosidase-IN-26 can be used in the study of type 2 diabetes mellitus (T2DM) .
|
-
- HY-149409
-
|
Glucosidase
|
Metabolic Disease
|
α-Glucosidase-IN-31 (compound R1) is an orally active, potent α-Glucosidase inhibitor with an IC50 value of 10.1 μM. α-Glucosidase-IN-31 significantly reduces the blood glucose level and has antidiabetic activity .
|
-
- HY-161281
-
|
Glucosidase
|
Metabolic Disease
|
α-Glucosidase-IN-49 (compound C23) is a potent inhibitor of α-Glucosidase, with IC50 of 0.52 μM. α-Glucosidase-IN-49 has oral bioactivity that can reduce blood glucose and improve glucose tolerance in mice .
|
-
- HY-146981
-
-
- HY-163005
-
|
Glucosidase
|
Metabolic Disease
|
α-Glucosidase-IN-43 (compound AS14) is an α-glucosidase inhibitor (IC50: 4.32 μM) with acute hypoglycemic activity. α-Glucosidase-IN-43 exhibits safety and in vivo efficacy, is nontoxic to normal mouse fibroblasts, and is able to rescue streptozotocin (HY-13753)-induced diabetic rats. α-Glucosidase-IN-43 can be used to study postprandial hyperglycemia in diabetic patients .
|
-
- HY-161411
-
|
Glucosidase
|
Metabolic Disease
|
α-Glucosidase-IN-60 (Compound 5k) exhibits a competitive inhibitory efficacy against α-Glucosidase, with IC50 of 10.8 μM .
|
-
- HY-162169
-
|
Amylases
Glucosidase
|
Metabolic Disease
|
α-Amylase/α-Glucosidase-IN-8 (Compound 7p) is a potent dual inhibitor of α-amylase and α-glucosidase, with IC50s of 10.19 and 10.33 μM, respectively. α-Amylase/α-Glucosidase-IN-8 has good anti-oxidant activity(IC50 = 14.93 μM). α-Amylase/α-Glucosidase-IN-8 can be used for the research of diabetes .
|
-
- HY-152158
-
|
Glucosidase
|
Metabolic Disease
|
α-Glucosidase-IN-22 (compound 7i), a benzimidazole, is a potent α-glucosidase inhibitor with an IC50 of 0.64 μM. α-Glucosidase-IN-22 is a potent anti-diabetic agent and has the potential for type 2 diabetes mellitus (T2DM) research .
|
-
- HY-154972
-
|
Glucosidase
Amylases
|
Metabolic Disease
|
α-Amylase/α-Glucosidase-IN-3 (Compound 17) is an α-Amylase/α-Glucosidase dual inhibitor, with IC50s of 0.70 μM and 1.10 μM. α-Amylase/α-Glucosidase-IN-3 can be used for research of type-II diabetes mellitus .
|
-
- HY-149557
-
|
Glucosidase
Amylases
|
Metabolic Disease
|
α-Amylase/α-Glucosidase-IN-5 (compound 4l) is a dual inhibitor of α-glucosidase (Glucosidase) and α-amylase (Amylases) with IC50s of 5.96 μM and 1.62 μM, respectively. α-Amylase/α-Glucosidase-IN-4 has potential antidiabetic activity .
|
-
- HY-155241
-
|
Glucosidase
Amylases
|
Metabolic Disease
|
α-Amylase/α-Glucosidase-IN-4 (compound 5) is a dual inhibitor of α-glucosidase (Glucosidase) and α-amylase (Amylases) with IC50s of 0.15 μM and 1.10 μM, respectively. α-Amylase/α-Glucosidase-IN-4 has potential antidiabetic activity .
|
-
- HY-156380
-
|
Amylases
Glucosidase
|
Metabolic Disease
|
α-Amylase/α-Glucosidase-IN-6 (compound 5j) is a potent dual inhibitor of α-amylase and α-glucosidase, with IC50s of 17.0 and 40.1 µM, respectively. α-Amylase/α-Glucosidase-IN-6 exhibits anti-hyperglycemic activities .
|
-
- HY-N2223
-
Ganodermadiol
|
|
|
Ganoderol B is a potent α-glucosidase inhibitor. Ganoderol B has high α-glucosidase inhibition with an IC50 of 48.5 μg/mL (119.8 μM) .
|
-
- HY-162036
-
|
Glucosidase
Amylases
Cholinesterase (ChE)
|
Neurological Disease
Metabolic Disease
|
α-Amylase/α-Glucosidase-IN-7 (Compound 3f) is a competitive α-glucosidase and α-amylase enzyme inhibitor with IC50 values of 18.52 and 20.25 µM, respectively. α-Amylase/α-Glucosidase-IN-7 can also effectively inhibit AChE and BChE, with IC50 values of 9.25 and 10.06 µM respectively. α-Amylase/α-Glucosidase-IN-7 can be used in diabetes and Alzheimer’s research .
|
-
- HY-P2802
-
α-D-Glucosidase
|
Glucosidase
|
Metabolic Disease
|
α-Glucosidase (α-D-Glucosidase), a carbohydrate hydrolyzing enzyme, catalyzes the liberation of α-glucose from the non-reducing end of the substrate. α-Glucosidase can facilitate the absorption of glucose by the small intestine. Inhibition of α-Glucosidase is an effective management of non-insulin-dependent diabetes mellitus (NIDDM) .
|
-
- HY-163433
-
|
Glucosidase
|
Metabolic Disease
|
α-Glucosidase-IN-57 (Compound 10c) is a competitive and orally active α-glucosidase inhibitor with an IC50 value of 0.180 μM and a Ki of 0.15 μM. α-Glucosidase-IN-57 can reduce fasting and overall blood glucose levels in mice, and can be used for anti-diabetes research .
|
-
- HY-158037
-
|
Glucosidase
|
Metabolic Disease
|
α-Glucosidase-IN-55 (Compound 8g) is an orally active and competitive alpha-glucosidase inhibitor, with IC50 and Ki values of 12.1 and 9.66 µM, respectively. α-Glucosidase-IN-55 can be used for the research into type 2 diabetes mellitus (T2DM) to improve blood sugar control and metabolic health .
|
-
- HY-146305
-
-
- HY-149532
-
|
Glucosidase
|
Metabolic Disease
|
α-Glucosidase-IN-33 (compound 7c) is a potent α-glucosidase inhibitor (IC50: 2.39 μM) and can be used in the study of type 2 diabetes and hyperglycemia .
|
-
- HY-149533
-
|
Glucosidase
|
Metabolic Disease
|
α-Glucosidase-IN-34 (compound 7f) is a potent α-glucosidase inhibitor (IC50: 2.90 μM) and can be used in the study of type 2 diabetes and hyperglycemia .
|
-
- HY-N0374
-
|
Glucosidase
|
Metabolic Disease
|
Licochalcone C could inhibit α-glucosidase, with IC50s of <100 nM and 92.43 μM for α-glucosidase and protein tyrosine phosphatase 1B (PTP1B), respectively.
|
-
- HY-W011411
-
|
Glucosidase
|
Others
|
4-Nitrophenyl a-D-glucopyranoside is a chromogenic substrate for α-glucosidase. 4-Nitrophenyl a-D-glucopyranoside can be used to measure of α-glucosidase activity .
|
-
- HY-146984
-
|
Glucosidase
|
Inflammation/Immunology
|
α-Glucosidase-IN-3 is an oleanolic acid (OA) oxime ester derivative against α-glucosidase (IC50=1.28 µM) and α-amylase (IC50=3.8 µM) .
|
-
- HY-155030
-
|
Glucosidase
|
Metabolic Disease
|
α-Glucosidase-IN-25 (Compound (R)-8k) is a competitive inhibitor of α-glucosidase, with an IC50 of 1.19μM and can be used for anti-diabetic research .
|
-
- HY-N8120
-
-
- HY-155105
-
|
Glucosidase
|
Metabolic Disease
|
α-Glucosidase-IN-30 (compound 8c) is a potent, orally active, competitive inhibitor against α-glucosidase, with Ki of 40.0 µM and IC50 value of 49.0 µM. α-Glucosidase-IN-30 is non-cytotoxic against the cancer and normal cell lines MCF-7 and HDF, and can be used for Type 2 diabetes study .
|
-
- HY-125713
-
|
Glucosidase
Enterovirus
|
Infection
|
Ganoderic acid Y is a α-glucosidase inhibitor with an IC50 of 170 μM for yeast α-glucosidase. Ganoderic acid Y inhibits enterovirus 71 (EV71) replication through blocking EV71 uncoating .
|
-
- HY-161355
-
|
Amylases
Glucosidase
|
Metabolic Disease
|
α-Amylase/α-Glucosidase-IN-9 (compound 5h) is a dual inhibitor for both α-amylase (IC50 = 16.4 μM) and α-glucosidase (IC50 = 31.6 μM) enzymes .
|
-
- HY-U00090
-
MOR 14; N-Methyl-1-deoxynojirimycin; N-Methylmoranolin
|
Glucosidase
|
Metabolic Disease
|
N-Methylmoranoline (MOR 14) is an α-glucosidase inhibitor.
|
-
- HY-N3962
-
-
- HY-162373
-
|
Amylases
Glucosidase
P-glycoprotein
|
Metabolic Disease
|
α-Amylase/α-Glucosidase-IN-10 (compound 5d) is an α-amylase and α-glucosidase inhibitor (IC50: 30.39 μM and 65.1 μM) with potential diabetes inhibitory effects. α-Amylase/α-Glucosidase-IN-10 exhibits high gastrointestinal (GI) absorption in ADMET (Absorption, Distribution, Metabolism, Excretion and Toxicity) prediction. While α-Amylase/α-Glucosidase-IN-10 acts as a substrate for P-gp and does not cross the blood-brain barrier (BBB), there may be a risk of central nervous system side effects .
|
-
- HY-119593
-
-
- HY-N0466
-
-
- HY-U00266
-
-
- HY-N1901
-
|
|
|
(E)-p-Coumaramide is an α-Glucosidase inhibitor that can be isolated from Welsh onion .
|
-
- HY-N1881
-
|
|
|
4',5-Dihydroxyflavone is a soybean LOX-1 and yeast α-Glucosidase inhibitor, with an Ki of 102.6 μM for soybean LOX-1 and an IC50 of 66 μM for yeast α-glucosidase. LOX-1 isshort for Lectin-like oxidized low-density lipoprotein receptor-1.
|
-
- HY-N4258
-
|
Glucosidase
|
Metabolic Disease
|
Panasenoside is a flavonoid isolated from Lilium pumilum DC. Panasenoside exhibits α-glucosidase inhibitory activity .
|
-
- HY-N3101
-
-
- HY-N3503
-
|
Glucosidase
|
Endocrinology
|
Ganoderlactone D shows inhibitory effects of yeast α-Glucosidase with IC50 values of 41.7 μM .
|
-
- HY-W009417
-
|
Glucosidase
|
Metabolic Disease
|
Cedryl acetate is a tricyclic sesquiterpene isolated from the plant Cunninghamia lanceolata. Cedryl acetate shows α-glucosidase inhibitory activity .
|
-
- HY-131114
-
|
Others
|
Others
|
Valiolamine is an aminocyclitol. Valiolamine has potent alpha-glucosidase inhibitory activity against porcine intestinal sucrase, maltase and isomaltase .
|
-
- HY-N7809
-
|
Others
|
Cancer
|
Pelargonidin 3-galactoside chloride is a major anthocyanin with anticancer effects. Pelargonidin 3-galactoside chloride inhibits α-glucosidase .
|
-
- HY-132179
-
-
- HY-N9317
-
|
Glucosidase
|
Metabolic Disease
|
Tangshenoside I, isolated from the roots of Codonopsis lanceolata, exhibits weak α-glucosidase inhibitory activities in vitro with an IC50 of 1.4 mM .
|
-
- HY-N2929
-
|
Glucosidase
|
Cardiovascular Disease
|
β-Hydroxypropiovanillone, a natural compound, shows significant concentration-dependent inhibitory effects on α-glucosidase with an IC50 of 257.8 μg/mL .
|
-
- HY-N11530
-
|
Glucosidase
|
Metabolic Disease
|
Kouitchenside G is a natural product that can be isolated from Swertia kouitchensis. Kouitchenside G inhibits α-Glucosidase with an IC50 of 956 μM .
|
-
- HY-108828
-
rhGAA
|
Others
|
Others
|
Alglucosidase alfa is a hydrolytic lysosomal glycogen-specific recombinant human α-glucosidase product. Alglucosidase alfa can be used for Pompe disease research .
|
-
- HY-E70183
-
EC:3.2.1.20; GAA
|
Biochemical Assay Reagents
|
Others
|
Lysosomal α-Glucosidase (EC:3.2.1.20) is a γ-amylase with specificity for glycogen and several natural and synthetic oligoglucosides .
|
-
- HY-119821
-
|
Glucosidase
|
Infection
|
Terphenyllin is a naturally abundant p-terphenyl metabolite isolated from the coral derived fungus Aspergillus candidus, has significant α-glucosidase inhibitory activity .
|
-
- HY-131504A
-
|
Glucosidase
|
Metabolic Disease
|
Valienamine is the alpha-glucosidase inhibitor. Valienamine is the key functional component of many natural glycosidase inhibitors including the crop protectant validamycin A and the antidiabetic agent acarbose .
|
-
- HY-N10426
-
|
Glucosidase
|
Metabolic Disease
|
(+)-Cembrene A (Compound 5) is a α-glucosidase inhibitor with an IC50 of 30.31 μM. (+)-Cembrene A is nontoxic towards human normal hepatocyte (LO2) cells .
|
-
- HY-129131
-
|
Glucosidase
|
Metabolic Disease
|
Chrysin 6-C-arabinoside 8-C-glucoside is a α±-glucosidase inhibitors which are widely used in the study for type 2 diabetes .
|
-
- HY-N1820
-
|
|
|
3α-Akebonoic acid is a α-glucosidase inhibitor with an IC50 value of 0.035 mM. 3α-Akebonoic acid shows antibacterial activity and cytotoxicity .
|
-
- HY-N7203
-
|
Glucosidase
|
Metabolic Disease
|
N-Caffeoyl O-methyltyramine is a class of alkaloid isolated from Cuscuta reflexa with strong inhibitory activity against α-glucosidase (IC50 of 103.58 μM) .
|
-
- HY-N1218
-
|
|
|
Stellasterol is a natural product. Stellasterol has high affinity towards Bcl-2 protein (Ki: 118.05 nM). Stellasterol is a weak α-glucosidase inhibitor .
|
-
- HY-121811
-
-
- HY-N12500
-
|
Glucosidase
|
Others
|
1'-O-Methyl neochebulinate, hydrolyzable tannin, is an α-glucosidase inhibitor with IC50 value of 59.5 μM, isolated from the fruits of Terminalia chebula Retz .
|
-
- HY-16134
-
MBI 3253; MDL 28574; MX3253
|
Flavivirus
Dengue virus
Glucosidase
HCV
HIV
|
Infection
|
Celgosivir (MBI 3253; MDL 28574; MX3253) is an α-glucosidase I inhibitor; inhibits bovine viral diarrhoea virus (BVDV) with an IC50 of 1.27 μM in in vitro assay.
|
-
- HY-16134A
-
MBI 3253 hydrochloride; MDL 28574 hydrochloride; MX3253 hydrochloride
|
Flavivirus
Dengue virus
Glucosidase
HCV
HIV
|
Infection
|
Celgosivir hydrochloride (MBI 3253 hydrochloride; MDL 28574 hydrochloride; MX3253 hydrochloride) is an α-glucosidase I inhibitor; inhibits bovine viral diarrhoea virus (BVDV) with an IC50 of 1.27 μM in in vitro assay.
|
-
- HY-N4095
-
-
- HY-N8018
-
-
- HY-N10606
-
|
Glucosidase
|
Metabolic Disease
|
Uvagrandol potently inhibits α-glucosidase and porcine lipase (IC50: 15.2 μM, 11.2 μM respectively). Uvagrandol can be used in the research of Type 2 diabetes and obesity .
|
-
- HY-N10969
-
|
Others
|
Others
|
(+)-5,7,4'-Trimethoxyafzelechin is a derivative of (+)-Afzelechin HY-N2821. (+)-Afzelechin is an α-glucosidase activity inhibitor. (+)-Afzelechin can be isolated from rhizomes of Bergenia ligulata .
|
-
- HY-B0089
-
BAY g 5421
|
Glucosidase
|
Metabolic Disease
|
Acarbose (BAY g 5421), antihyperglycemic agent, is an orally active alpha-glucosidase inhibitor (IC50=11 nM). Acarbose can potentiate the hypoglycemic effects of sulfonylureas or insulin .
|
-
- HY-N7095
-
CTZ
|
Bacterial
Antibiotic
|
Infection
|
Ceftezole (CTZ) is a broad-spectrum cephem antibiotic against many species of gram-positive and gram-negative bacteria. Ceftezole (CTZ) is an alpha-glucosidase inhibitor with in vivo anti-diabetic activity .
|
-
- HY-N7096
-
CTZ sodium
|
|
|
Ceftezole sodium (CTZ sodium) is a broad-spectrum cephem antibiotic against many species of gram-positive and gram-negative bacteria. Ceftezole sodium (CTZ sodium) is an alpha-glucosidase inhibitor with in vivo anti-diabetic activity .
|
-
- HY-146128
-
|
Glucosidase
|
Metabolic Disease
|
Anti-hyperglycemic agent-1 (compound 10) is a potent α-Glucosidase inhibitor, with an IC50 of 0.53 μM. Anti-hyperglycemic agent-1 can be used for diabetes research .
|
-
- HY-N10413
-
|
Glucosidase
|
Metabolic Disease
|
Diphlorethohydroxycarmalol, a kind of phlorotannin, is an orally active α-glucosidase and α-amylase inhibitor with IC50s of 0.16 mM and 0.53 mM, respectively. Diphlorethohydroxycarmalol has anti-diabetic activities .
|
-
- HY-N6575
-
-
- HY-122782
-
Lucialdehyde C
|
Glucosidase
|
Metabolic Disease
Cancer
|
Lucidal (Lucialdehyde C) is a natural lanostante-type triterpene aldehyde that shows inhibitory effects against α-glucosidase (Glucosidase) with an IC50 of 0.635 mM. Lucidal has anticancer and antidiabetic effects .
|
-
- HY-N10076
-
-
- HY-N11840
-
|
Glucosidase
|
Metabolic Disease
|
Mortatarin F (Compound 1) is an inhibitor of α‑glucosidase with an IC50 of 8.7 μΜ. Mortatarin F is an renylated flavonoid that can be isolated from mulberry leaves and can be used for hypoglycemic research .
|
-
- HY-N2809
-
|
Others
|
Others
|
Acantrifoside E (Compound 8) is a nature compound. Acantrifoside E can be isolated from the 90% ethanol extract of Salacia cochinchinensis. Acantrifoside E has none α-glucosidase inhibitory activity .
|
-
- HY-N9075
-
|
Glucosidase
|
Cancer
|
9-(4′-Hydroxyphenyl)-2-methoxyphenalen-1-one is a phytoalexin and mixed competitive α-glucosidase inhibitor of Bacillus stearothermophilus (IC50: 3.86 mg/L) .
|
-
- HY-N4195
-
Resveratrol glycoside; trans-Resveratrol 4'-O-β-D-glucopyranoside
|
Glucosidase
|
Cardiovascular Disease
Metabolic Disease
|
Resveratroloside (Resveratrol glycoside) is a competitive inhibitior of α-glucosidase with an IC50 of 22.9 μM. Resveratroloside has the ability to regulate PBG (postprandial blood glucose) levels. Resveratroloside exhibits cardioprotective effect .
|
-
- HY-N8947
-
|
Endogenous Metabolite
Glucosidase
|
Metabolic Disease
|
Glyurallin A (Compound 79) is isolated from the
naturalGlycyrrhiza uralensis. Glyurallin A inhibitsα-Glucosidase(HY-P2802)(IC50=0.3 μM). Glyurallin A
can be used in the study of anti-diabetes .
|
-
- HY-N11841
-
|
Glucosidase
|
Metabolic Disease
|
Mortatarin G (compound 3) is a prenylated flavonoid, that can be isolated from mulberry leaves. Mortatarin G exhibits good α-glucosidase inhibitory activity, with an IC50 of 20.4±1.4 μM .
|
-
- HY-N12138
-
|
Glucosidase
|
Metabolic Disease
|
Flaccidoside III is a flavonoid and triterpenoid isolated from the aerial parts of N. sativa (Ranunculaceae). Flaccidoside III inhibits α-Glucosidase (IC50: 256.7 μM) and has potential antioxidant and antidiabetic activities .
|
-
- HY-N7763
-
|
Glucosidase
|
Neurological Disease
|
Casuarictin is a potent and competitive α-glucosidase inhibitor with an IC50 of 0.21 μg/mL. Casuarictin is a presenilin stabilization factor like protein (PSFL) protein inhibitor. Casuarictin can be used for Alzheimer's disease research .
|
-
- HY-N2703
-
|
Glucosidase
|
Metabolic Disease
|
6β-Hydroxyipolamiide can be isolated from the methanolic extract of S. jamaicensis leaves. 6β-Hydroxyipolamiide has α-glucosidase inhibitory activity with an IC50 of 539.17 μg/mL .
|
-
- HY-B0089A
-
Bay-g 5421 sulfate
|
Glucosidase
|
Metabolic Disease
|
Acarbose (BAY g 5421) sulfate, antihyperglycemic agent, is an orally active alpha-glucosidase inhibitor (IC50=11 nM). Acarbose sulfate can potentiate the hypoglycemic effects of sulfonylureas or insulin .
|
-
- HY-N3431
-
|
Glucosidase
|
Metabolic Disease
|
Kaempferol-7-O-rhamnoside, isolated from Chimonanthus nitens Oliv. Leaves, is a potent α-glucosidase activity inhibitor. Kaempferol-7-O-rhamnoside has the potential for diabetes .
|
-
- HY-N8517
-
|
Glucosidase
Apoptosis
|
Infection
Metabolic Disease
Cancer
|
Malabaricone B, a naturally occurring plant phenolic, is an orally active α-glucosidase inhibitor with an IC50 of 63.7 µM. Malabaricone B has anticancer, antimicrobial, anti-oxidation and antidiabetic activities .
|
-
- HY-N10002
-
|
Phosphatase
Glucosidase
|
Metabolic Disease
|
Caffeoyltryptophan is a competitive PTP1B inhibitor, with an IC50 of 16.99 μM. Caffeoyltryptophan can also inhibit α-glucosidase, linoleic acid peroxidation and haemolysis. Caffeoyltryptophan can be used for the research of type 2 diabetes .
|
-
- HY-N10064
-
|
Others
|
Metabolic Disease
|
Ficusonolide has significant antidiabetic activity with a possible mechanism of interaction with dipeptidyl peptidase-IV (DPP-IV), protein tyrosine phosphatase 1B (PTP-1B), α-glucosidase, and α-amylase.
|
-
- HY-143268
-
|
Amylases
Glucosidase
|
Metabolic Disease
|
HPA-IN-1 (Compound 1) is a potent and selective human pancreatic α-amylase (HPA) inhibitor with IC50 values of 12.0 μM and 410.4 μM against HPA and α-glucosidase, respectively .
|
-
- HY-N7729
-
|
Amylases
Glucosidase
|
Metabolic Disease
|
Sekikaic acid is an α-glucosidase (Glucosidase) and α-amylase (Amylases) inhibitor with hypolipidemic, antioxidant and antidiabetic activities. Sekikaic acid significantly reduces LDL, total cholesterol, and total glyceride levels and causes pancreatic beta cell regeneration .
|
-
- HY-107532
-
NN-DNJ; Nonyl-DNJ
|
Glucosidase
|
Metabolic Disease
|
N-Nonyldeoxynojirimycin (NN-DNJ) is a potent inhibitor of alpha-glucosidase and alpha-1,6-glucosidase (IC50s, 0.42, 8.4 μM, respectively), inhibits glycogen breakdown .
|
-
- HY-N2821
-
|
Glucosidase
|
Metabolic Disease
|
(+)-Afzelechin, isolated from rhizomes of Bergenia ligulata, is an alpha-glucosidase activity inhibitor with an ID50 (50% inhibition dose) value of 0.13 mM. (+)-Afzelechin can delay the absorption of carbohydrates in food to suppress postprandial hyperglycemia and hyperinsulinemia .
|
-
- HY-143269
-
|
Amylases
Glucosidase
|
Metabolic Disease
|
HPA-IN-2 (Compound 2a-1) is a potent and selective human pancreatic α-amylase (HPA) inhibitor with IC50 values of 8.2 μM and 450.7 μM against HPA and α-glucosidase, respectively .
|
-
- HY-161150
-
-
- HY-N7377
-
|
Glucosidase
|
Metabolic Disease
|
Butyl isobutyl phthalate is isolated from the rhizoid of Laminaria japonica. Butyl isobutyl phthalate is a non-competitive α-glucosidase inhibitor with an IC50 value of 38 μM. Butyl isobutyl phthalate shows a hypoglycemic effect and has the potential for diabetes treatment .
|
-
- HY-14860
-
Duvoglustat
|
Glucosidase
PI3K
|
Metabolic Disease
|
1-Deoxynojirimycin (Duvoglustat) is a potent and orally active α-glucosidase inhibitor. 1-Deoxynojirimycin suppresses postprandial blood glucose and is widely used for diabetes mellitus. 1-Deoxynojirimycin possesses antihyperglycemic, anti-obesity, and antiviral features .
|
-
- HY-14860A
-
Duvoglustat hydrochloride
|
Glucosidase
PI3K
Bacterial
Antibiotic
|
Infection
Metabolic Disease
|
1-Deoxynojirimycin hydrochloride (Duvoglustat hydrochloride) is a potent and orally active α-glucosidase inhibitor. 1-Deoxynojirimycin hydrochloride suppresses postprandial blood glucose and is widely used for diabetes mellitus. 1-Deoxynojirimycin hydrochloride possesses antihyperglycemic, anti-obesity, and antiviral features .
|
-
- HY-126067
-
|
Glucosidase
Apoptosis
|
Inflammation/Immunology
|
(-)-Pinoresinol is a plant-derived tetrahydrofuran lignan that inhibits α-glucosidase and acts as a hypoglycemic agent. (-)-Pinoresinol has some anti-inflammatory effects and acts as a chemopreventive agent, inducing increased apoptosis and cell cycle G2/M arrest .
|
-
- HY-N12006
-
|
Glucosidase
|
Others
|
6,8-Dihydroxy-1,2,7-trimethoxy-3-methylanthraquinone (compound 1) is an anthraquinone α-glucosidase inhibitor (IC50:185 μM), which can be isolated from Cassia seeds .
|
-
- HY-N1186
-
|
|
|
Tachioside inhibits nitric oxide production in lipopolysaccharide (HY-D1056)-stimulated RAW 264.7 cells with IC50 value of 12.14 μM. Tachioside has anti-obesity, antioxidant and α-glucosidase inhibitory activities .
|
-
- HY-N1510
-
|
Glucosidase
|
Metabolic Disease
|
Kaempferol 3-O-gentiobioside is a flavonoid isolated from C. alata leaves with antidiabetic activity. Kaempferol 3-O-gentiobioside possesses activity against α-glucosidase and displays carbohydrate enzyme inhibitory effect with an IC50 of 50.0 µM .
|
-
- HY-N3078
-
|
Glucosidase
|
Endocrinology
|
p-Hydroxyphenethyl trans-ferulate has anti-hyperglycemic(yeast α-glucosidase,IC50 19.24 ± 1.73 µmol L-1), antioxidant, and anti-inflammatory activities . p-Hydroxyphenethyl trans-ferulate shows inhibiting cancer preve
|
-
- HY-N10294
-
|
HIV
|
Infection
Inflammation/Immunology
|
Epicoccone B, firstly reported from C. globosum, exhibits the DPPH free radical scavenging ability with IC50 value of 10.8 μM, and has potent α-glucosidase inhibition with IC50 value of 27.3 μM. Anti-HIV activity .
|
-
- HY-N7599
-
|
Phosphatase
Glucosidase
|
Metabolic Disease
|
Chrysophanol triglucoside is an anthraquinone isolated from Cassia obtusifolia, inhibits protein tyrosine phosphatases 1B (PTP1B) and α-glucosidase with IC50s of 80.17 and 197.06 µM, respectively. Chrysophanol triglucoside has the potential for diabetes research .
|
-
- HY-163335
-
-
- HY-N6005
-
|
Bacterial
|
Infection
Cancer
|
Methyl caffeate, an antimicrobial agent, shows moderate antimicrobial and prominent antimycobacterial activities. Methyl caffeate also exhibits α-glucosidase inhibition activity, oxidative stress inhibiting activity, anti-platelet activity, antiproliferative activity in cervix adenocarcinoma and anticancer activity in lung and leukmia cell lines .
|
-
- HY-N3542
-
|
Glucosidase
|
Cancer
|
Carpachromene is a potent α-glucosidase enzyme inhibitor. Carpachromene ameliorates insulin resistance in HepG2 cells via modulating IR/IRS1/PI3k/Akt/GSK3/FoxO1 pathway .
|
-
- HY-154995
-
|
Others
|
Infection
|
N-4′-(p-Trifluoromethylphenyl)butyl-DAB (compound 5g) is an agonit of lysosomal acid α-glucosidase (GAA). N-4′-(p-Trifluoromethylphenyl)butyl-DAB increases intracellular GAA activities dose-dependently, in Pompe patient's fibroblasts with the M519V mutation .
|
-
- HY-N11999
-
|
Others
|
Others
|
5,4'-Dihydroxy-3,4,3'-trimethoxybibenzyl (compound 8) can be isolated from Dendrobium infundibulum (D. infundibulum). 5,4'-Dihydroxy-3,4,3'-trimethoxybibenzyl has no inhibitory activity against α-glucosidase and pancreatic lipase .
|
-
- HY-B0025
-
|
Glucosidase
|
Metabolic Disease
|
Voglibose is an orally active alpha-glucosidase inhibitor that prevents the development of colorectal precancerous lesions induced by obesity and diabetes. Voglibose reduces oxidative stress in an inflammatory environment and inhibits the insulin-like growth factor/insulin-like growth factor-1 receptor (IGF/IGF-1R) functional axis.
|
-
- HY-B0986
-
4-Hexylresorcinol
|
Parasite
Bacterial
Apoptosis
Glucosidase
Endogenous Metabolite
|
Infection
Metabolic Disease
Cancer
|
Hexylresorcinol (4-Hexylresorcinol) is a natural compound found in plants with antimicrobial, anthelmintic, antiseptic and antitumor activities. Hexylresorcinol can induce apoptosis in squamous carcinoma cells. Hexylresorcinol is a reversible and noncompetitive inhibitor of α-glucosidase. Hexylresorcinol has protective effects against oxidative DNA damage .
|
-
- HY-N7626
-
|
Fungal
Glucosidase
|
Infection
|
Eleutherol is a naphthalene isolated from E. americana with antifungal activities . Eleutherol is against yeasts Candida albicans, C. tropicalis, Saccharomyces cerevisiae and Cryptococcus neoformans with MIC values between 7.8 µg/mL and 250 µg/mL . Eleutherol inhibits α-glucosidase function with an IC50>1.00 mM .
|
-
- HY-113133
-
|
Glucosidase
|
Infection
Metabolic Disease
Inflammation/Immunology
|
Kojibiose, an orally active prebiotic disaccharide, can specifically inhibit the activity of α-glucosidase I. kojibiose is a proliferation factor for Bifidobacterium, lactic acid bacteria, and eubacteria. kojibiose is a low-calorie sweetener capable of increasing the absorption of iron. Kojibiose exhibits antitoxic activity. Kojibiose reduces hepatic expression of inflammatory markers in vivo .
|
-
- HY-126535
-
|
Glucosidase
|
Metabolic Disease
Cancer
|
Magnoloside B is an α-glucosidase inhibitor (IC50=0.69 mM), which can be obtained from Magnolia officinalis stem bark. Magnoloside B shows moderate inhibitory activity against MGC-803 and HepG2 cells. Magnoloside B has the potential to study cancer and diabetes .
|
-
- HY-N7683
-
|
Glucosidase
|
Metabolic Disease
|
Prunetin 5-O-β-D-glucopyranoside is an isoflavone isolated from extracts of Potentilla astracanica. Prunetin 5-O-β-D-glucopyranoside is a potent and uncompetitive inhibitor of α-glucosidase, with an IC50 of 56.05 μg/mL. Prunetin 5-O-β-D-glucopyranoside can be used for the research of type-2 diabetes .
|
-
- HY-N10360
-
|
Dipeptidyl Peptidase
|
Metabolic Disease
|
Ellipyrone A, a γ-pyrone enclosed macrocyclic poyketide, shows inhibition potential against dipeptidyl peptidase-4 (IC50=0.35 mM). Ellipyrone A also has anti-carbolytic property against α-glucosidase (IC50=0.74 mM) and α-amylase (IC50=0.59 mM) .
|
-
- HY-N10440
-
|
Glucosidase
|
Infection
Inflammation/Immunology
|
3-Oxo-hop-22(29)-ene is a yeast α-glucosidase inhibitor. 3-Oxo-hop-22(29)-ene shows a moderate effect on the viability of T. cruzi and L. mexicana. 3-Oxo-hop-22(29)-ene shows marginal activity of anti-inflammatory .
|
-
- HY-N2574
-
|
Glucosidase
|
Metabolic Disease
|
Gitogenin is a natural steroid isolated from the whole plant of Tribulus longipetalus. Gitogenin is a selective inhibitor of UDP-glucuronosyltransferase 1A4 (UGT1A4) and enzyme α-glucosidase with IC50 values of 0.69 μM (use trifluoperazine as a substrate) and 37.2 μM, respectively, and does not inhibit the activities of major human cytochrome P450 isoforms .
|
-
- HY-N1029
-
Mangiferitin
|
|
|
Norathyriol (Mangiferitin) is a natural metabolite of Mangifera. Norathyriol inhibits α-glucosidase in a noncompetitive manner with an IC50 of 3.12 μM . Norathyriol inhibits PPARα, PPARβ, and PPARγ with IC50s of 92.8 µM, 102.4 µM, and 153.5 µM, respectively . Antioxidant, anticancer, antimicrobial, anti-inflammatory, anti-bacterial activities.
|
-
- HY-N9283
-
|
Reactive Oxygen Species
|
Neurological Disease
Cancer
|
1,2-Diacetoxy-4,7,8-trihydroxy-3-(4-hydroxyphenyl)dibenzofuran, isolated from the edible mushroom Sarcodon leucopus, has antioxidant effects in the DPPH scavenging assay with the IC50 of 28 μM, inhibits malondialdehyde (MDA) with the IC50 of 71 μM, and inhibits α-glucosidase with the IC50 of 6.22 μM .
|
-
- HY-N9051
-
|
Glucosidase
|
Inflammation/Immunology
Cancer
|
6-Prenylquercetin-3-Me ether is a natural product that can be extracted from G. uralensis leaves.
6-Prenylquercetin-3-Me ether has radical scavenging activity toward DPPH. 6-Prenylquercetin-3-Me ether also has inhibitory activity against α-glucosidase .
|
-
- HY-N7170
-
|
Glucosidase
|
Metabolic Disease
|
(-)-6β-Hydroxy-5β,8β,9β,10α-cleroda-3,13-dien-16,15-olid-18-oic acid (compound 4) is a α-Glucosidase inhibitor with an IC50 value of 577.7 µM .
|
-
- HY-155961
-
-
- HY-N1839
-
|
Apoptosis
Glucosidase
|
Cancer
|
3-Hydroxybakuchiol can be isolated from Otholobium mexicanum J. W. Grimes. 3-Hydroxybakuchiol is an electron transport chain (ETC) inhibitor. 3-Hydroxybakuchiol has antitumor activity, and induces tumor cell apoptosis. 3-Hydroxybakuchiol also has moderate inhibitory activity against α-glucosidase (IC50: 345 μM) .
|
-
- HY-N12688
-
|
Glucosidase
Amylases
|
Metabolic Disease
|
2,3-Dihydrocalodenin B (Compound 6) is a compound that can be isolated from Knema globularia. 2,3-Dihydrocalodenin B is a potent and non-competitive inhibitor against α-glucosidase and α-amylase, with IC50 values of 1.1 and 2.6 μM, respectively. 2,3-Dihydrocalodenin B can be used for the research of diabetes .
|
-
- HY-150723
-
|
Glucosidase
|
Metabolic Disease
|
PBI-6DNJ is an orally active and potent multivalent glycosidase inhibitor. PBI-6DNJ exhibits good inhibition activity against α-glucosidase from mice, with a Ki of 0.14 μM. PBI-6DNJ exhibits good hypoglycemic activity. PBI-6DNJ can be used for type 2 diabetes research .
|
-
- HY-163332
-
|
Glucosidase
Dipeptidyl Peptidase
Glutathione Peroxidase
|
Cardiovascular Disease
|
MPO-IN-6 (compound ADC) is an electrophile with good antioxidant and anti-inflammatory properties. MPO-IN-6 is a myeloperoxidase (MPO), dipeptidyl peptidase-4 (DPP-4), and α-glucosidase (α-GD) inhibitor with IC50s of 10 μM, 31.02 μM, and 46.05 μM, respectively. MPO-IN-6 is a potential cardiovascular preventive agent .
|
-
- HY-N0057
-
3,4-Di-O-caffeoylquinic acid; Isochlorogenic acid B
|
Glucosidase
Influenza Virus
Apoptosis
Endogenous Metabolite
|
Infection
Cancer
|
3,4-Dicaffeoylquinic acid (3,4-Di-O-caffeoylquinic acid), naturally isolated from Laggera alata, has antioxidative, DNA protective, neuroprotective and hepatoprotective properties. 3,4-Dicaffeoylquinic acid exerts apoptosis-mediated cytotoxicity and α-glucosidase inhibitory effects. 3,4-Dicaffeoylquinic acid possesses a unique mechanism of anti-influenza viral activity, that is, enhancing viral clearance by increasing TRAIL .
|
-
- HY-126052
-
|
COX
Tyrosinase
HDAC
|
Metabolic Disease
Cancer
|
Gnetol is a phenolic compound isolated from the root of Gnetum montanum . Gnetol potently inhibits COX-1 (IC50 of 0.78 μM) and HDAC. Gnetol is a potent tyrosinase inhibitor with an IC50 of 4.5 μM for murine tyrosinase and suppresses melanin biosynthesis. Gnetol has antioxidant, antiproliferative, anticancer and hepatoprotective activity. Gnetol also possesses concentration-dependent α-Amylase, α-glucosidase, and adipogenesis activities .
|
-
- HY-139663
-
|
Glucosidase
|
Infection
|
IHVR-17028 is a potent and broad-spectrum antiviral agent. IHVR-17028 exhibits antiviral activity against BVDV, TCRV and DENV with EC50 values of 0.4 μM, 0.26 μM, 0.3 μM, respectively. IHVR-17028 is a potent ER α-glucosidase I inhibitor with an IC50 of 0.24 μM. IHVR-17028 can be used for infectious diseases research .
|
-
- HY-N11728
-
|
Amylases
Glucosidase
|
Metabolic Disease
|
2,7"-Phloroglucinol-6,6'-bieckol is an orally active dual α-amylase/α-glucosidase inhibitor with IC50 values of 6.94 μM and 23.35 μM respectively. 2,7"-Phloroglucinol-6, 6'-bieckol alleviates postprandial hyperglycemia in diabetic mice. 2,7"-Phloroglucinol-6,6'-bieckol can be used in diabetes research .
|
-
- HY-N2025
-
|
PPAR
Glucosidase
|
Metabolic Disease
|
Oroxin A is the major component of an ethanol-water Oroxylum indicum (L.) Kurz (Bignoniaceae) seed extract (OISE). Oroxin A acts as a partial PPARγ agonist that can activate PPARγ transcriptional activation. Oroxin A activates PPARγ by docking into the PPARγ protein ligand-binding domain. Oroxin A also exhibits an inhibitory activity against α-glucosidase and an antioxidant capacity . Oroxin A exerts anti-breast cancer effects by inducing ER stress-mediated senescence .
|
-
- HY-N2925
-
β-Amyron
|
Fungal
COX
PPAR
|
Infection
Metabolic Disease
Inflammation/Immunology
|
β-Amyrone (β-Amyron) is a triterpene compound which has anti-inflammatory activity through inhibiting the expression of COX-2. β-Amyrone has antifungal activity , as well as antiviral activity against Chikungunya virus. β-Amyrone also inhibits α-glucosidase and acetylcholinesterase (AChE) activity. β-Amyrone can be used in the research of disease like inflammation, infection, and obesity .
|
-
- HY-P99803
-
VAL-1221
|
Glucosidase
|
Others
|
Clervonafusp alfa (VAL-1221) is a fusion protein targeting both cytosolic and lysosomal glycogen. Clervonafusp alfa is comprised of the Fab portion of a cell-penetrating antibody and recombinant human acid alpha glucosidase (rhGAA), the former utilizing the nucleoside transporter ENT-2 to gain access to the cytosol, and the latter enters lysosomes via mannose-6-phosphate receptors (M6PRs). Clervonafusp alfa can be used for late-onset Pompe disease research .
|
-
- HY-N2278
-
Leachianone E
|
Tyrosinase
Glucosidase
|
Cancer
|
Kushenol A (Leachianone E) is isolated from the root of Sophora flavescent. Kushenol A is a non-competitive tyrosinase inhibitor to block the conversion of L-tyrosine to L-DOPA, shows IC50 and Kivalues of 1.1 μM and 0.4 μM, respectively . Kushenol A is a flavonoid antioxidant, has inhibitory effects on alpha-glucosidase (IC50: 45 μM; Ki: 6.8 μM) and β-amylase . Kushenol A is confirmed as potential inhibitors of enzymes targeted by cosmetics for skin whitening and aging .
|
-
- HY-N10295
-
|
Aryl Hydrocarbon Receptor
|
Inflammation/Immunology
|
Flavipin is an aryl hydrocarbon receptor (Ahr) agonist that induces the expression of Ahr downstream genes in mouse CD4 + T cells and CD11b + macrophages. Flavipin inhibits the stabilizing function of Arid5a on Il23a 3′UTR, a newly identified target mRNA . Flavipin exhibits the DPPH free radical scavenging ability with IC50 value of 7.2 μM, and has potent α-glucosidase inhibition with IC50 value of 33.8 μM .
|
-
- HY-N8161
-
Kaempferol 3,7-diglucoside
|
Glucosidase
Cholinesterase (ChE)
|
Neurological Disease
|
Kaempferol-3,7-di-O-β-glucoside (Kaempferol 3,7-diglucoside), a flavonol, possesses enzyme inhibition property towards α-amylase, α-glucosidase and Acetylcholinesterase. Kaempferol-3,7-di-O-β-glucoside protects differentiating neuronal cells, SH-SY5Y from Amyloid β peptide-induced injury. Kaempferol-3,7-di-O-β-glucoside has the potential for Alzheimer's research .
|
-
- HY-N0058
-
Isochlorogenic acid C
|
HBV
Endogenous Metabolite
Apoptosis
Glucosidase
|
Infection
|
4,5-Dicaffeoylquinic acid (Isochlorogenic acid C) is an antioxidant, can be isolated from Gynura divaricata and Laggera alata. 4,5-Dicaffeoylquinic acid reduces islet cell apoptosis and improves pancreatic function in type 2 diabetic mice, and has obvious inhibitory activities against yeast α-glucosidase. 4,5-Dicaffeoylquinic acid inhibits prostate cancer cells through cell cycle arrest. 4,5-Dicaffeoylquinic acid also has anti-apoptotic, anti-injury and anti-hepatitis B virus effects .
|
-
- HY-N10439
-
|
Glucosidase
|
Inflammation/Immunology
|
3β-Acetoxy-hop-22(29)-ene (compound 1) is a potent anti-inflammatory agent. 3β-Acetoxy-hop-22(29)-ene shows high inhibitory activity of yeast α-glucosidase, with an IC50 of 5.74 μM. 3β-Acetoxy-hop-22(29)-ene inhibits MPO (myeloperoxidase) activity in a dose-dependent manner in mouse ear edema model induced by 12-O-tetradecanoylphorbol acetate (TPA), with an IC50 of 0.23 μmol/ear .
|
-
- HY-N11477
-
|
Glucosidase
|
Metabolic Disease
|
(2α,3β,4α)-2,3,19-Trihydroxyurs-12-ene-23,28-dioic acid is a saponin that can be isolated from Rubus ellipticus var. obcordatus. (2α,3β,4α)-2,3,19-Trihydroxyurs-12-ene-23,28-dioic acid inhibits α-Glucosidase with an IC50 of 1.68 mM .
|
-
- HY-N0946
-
(-)-Pinoresinol 4-O-β-D-glucopyranoside
|
Glucosidase
|
Metabolic Disease
|
(-)-Pinoresinol 4-O-glucoside ((-)-Pinoresinol 4-O-β-D-glucopyranoside) is a potent and orally active α-glucosidase inhibitor with an IC50 value of 48.13 µM. (-)-Pinoresinol 4-O-glucoside increases cell migration and early differentiation of pre-osteoblasts. (-)-Pinoresinol 4-O-glucoside increases protein level of BMP2, p-Smad1/5/8, RUNX2. (-)-Pinoresinol 4-O-glucoside attenuates oxidative stress, hyperglycemia and hepatic toxicity. (-)-Pinoresinol 4-O-glucoside has the potential for the research of osteoporosis and periodontal disease .
|
-
Cat. No. |
Product Name |
Type |
-
- HY-P2802
-
α-D-Glucosidase
|
Biochemical Assay Reagents
|
α-Glucosidase (α-D-Glucosidase), a carbohydrate hydrolyzing enzyme, catalyzes the liberation of α-glucose from the non-reducing end of the substrate. α-Glucosidase can facilitate the absorption of glucose by the small intestine. Inhibition of α-Glucosidase is an effective management of non-insulin-dependent diabetes mellitus (NIDDM) .
|
-
- HY-E70183
-
EC:3.2.1.20; GAA
|
Enzyme Substrates
|
Lysosomal α-Glucosidase (EC:3.2.1.20) is a γ-amylase with specificity for glycogen and several natural and synthetic oligoglucosides .
|
-
- HY-N11598
-
|
Biochemical Assay Reagents
|
α-GLU stands for α-glucosidase. α-GLU hydrolyzes starch and disaccharides via targeting to terminal, non-reducing (1→4)-linked α-D-glucose residues to produce α-glucose. α-GLU is substrate selective .
|
Cat. No. |
Product Name |
Target |
Research Area |
-
- HY-107532
-
NN-DNJ; Nonyl-DNJ
|
Glucosidase
|
Metabolic Disease
|
N-Nonyldeoxynojirimycin (NN-DNJ) is a potent inhibitor of alpha-glucosidase and alpha-1,6-glucosidase (IC50s, 0.42, 8.4 μM, respectively), inhibits glycogen breakdown .
|
Cat. No. |
Product Name |
Target |
Research Area |
-
- HY-P99803
-
VAL-1221
|
Glucosidase
|
Others
|
Clervonafusp alfa (VAL-1221) is a fusion protein targeting both cytosolic and lysosomal glycogen. Clervonafusp alfa is comprised of the Fab portion of a cell-penetrating antibody and recombinant human acid alpha glucosidase (rhGAA), the former utilizing the nucleoside transporter ENT-2 to gain access to the cytosol, and the latter enters lysosomes via mannose-6-phosphate receptors (M6PRs). Clervonafusp alfa can be used for late-onset Pompe disease research .
|
Cat. No. |
Product Name |
Category |
Target |
Chemical Structure |
- HY-14860
-
-
- HY-14860A
-
-
- HY-126067
-
-
- HY-N12006
-
-
- HY-N1510
-
-
- HY-N3078
-
-
- HY-N10294
-
-
- HY-N7599
-
-
- HY-N6005
-
-
- HY-N3542
-
-
- HY-N11999
-
-
- HY-B0025
-
-
- HY-B0986
-
-
- HY-N7626
-
-
- HY-126535
-
-
- HY-N7683
-
-
- HY-N10360
-
-
- HY-N10440
-
-
- HY-N2574
-
-
- HY-N9283
-
|
Microorganisms
Source classification
Phenols
Polyphenols
|
Reactive Oxygen Species
|
1,2-Diacetoxy-4,7,8-trihydroxy-3-(4-hydroxyphenyl)dibenzofuran, isolated from the edible mushroom Sarcodon leucopus, has antioxidant effects in the DPPH scavenging assay with the IC50 of 28 μM, inhibits malondialdehyde (MDA) with the IC50 of 71 μM, and inhibits α-glucosidase with the IC50 of 6.22 μM .
|
-
- HY-N9051
-
-
- HY-N7170
-
-
- HY-N1839
-
-
- HY-N12688
-
-
- HY-N0057
-
3,4-Di-O-caffeoylquinic acid; Isochlorogenic acid B
|
Infection
Caprifoliaceae
Classification of Application Fields
Ketones, Aldehydes, Acids
Source classification
Phenols
Polyphenols
Plants
Endogenous metabolite
Disease Research Fields
|
Glucosidase
Influenza Virus
Apoptosis
Endogenous Metabolite
|
3,4-Dicaffeoylquinic acid (3,4-Di-O-caffeoylquinic acid), naturally isolated from Laggera alata, has antioxidative, DNA protective, neuroprotective and hepatoprotective properties. 3,4-Dicaffeoylquinic acid exerts apoptosis-mediated cytotoxicity and α-glucosidase inhibitory effects. 3,4-Dicaffeoylquinic acid possesses a unique mechanism of anti-influenza viral activity, that is, enhancing viral clearance by increasing TRAIL .
|
-
- HY-126052
-
-
- HY-N11728
-
-
- HY-N2025
-
-
- HY-N2925
-
-
- HY-N2278
-
-
- HY-N10295
-
-
- HY-N8161
-
-
- HY-N0058
-
-
- HY-N10439
-
-
- HY-N11477
-
|
Triterpenes
Structural Classification
Terpenoids
Source classification
Rosaceae
Plants
Rubus ellipticus Smith
|
Glucosidase
|
(2α,3β,4α)-2,3,19-Trihydroxyurs-12-ene-23,28-dioic acid is a saponin that can be isolated from Rubus ellipticus var. obcordatus. (2α,3β,4α)-2,3,19-Trihydroxyurs-12-ene-23,28-dioic acid inhibits α-Glucosidase with an IC50 of 1.68 mM .
|
-
- HY-N0946
-
(-)-Pinoresinol 4-O-β-D-glucopyranoside
|
Structural Classification
Artemisia selengensis Turcz. ex Bess.
Source classification
Plants
Compositae
Saccharides
Monosaccharides
|
Glucosidase
|
(-)-Pinoresinol 4-O-glucoside ((-)-Pinoresinol 4-O-β-D-glucopyranoside) is a potent and orally active α-glucosidase inhibitor with an IC50 value of 48.13 µM. (-)-Pinoresinol 4-O-glucoside increases cell migration and early differentiation of pre-osteoblasts. (-)-Pinoresinol 4-O-glucoside increases protein level of BMP2, p-Smad1/5/8, RUNX2. (-)-Pinoresinol 4-O-glucoside attenuates oxidative stress, hyperglycemia and hepatic toxicity. (-)-Pinoresinol 4-O-glucoside has the potential for the research of osteoporosis and periodontal disease .
|
-
Your information is safe with us. * Required Fields.
Inquiry Information
- Product Name:
- Cat. No.:
- Quantity:
- MCE Japan Authorized Agent: